GLSI- Greenwich Lifesciences, Inc.
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.61M | $80.75M | +7.3K |
Activity
Buys and sells only
Transactions
10 filings · page 7
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2023 | Patel Snehal61 | CEO And CFO | Buy | 600 | $16.53 | $9,918.00 | - | -30.3% | -32.1% | |
| Feb 10, 2023 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $18.68 | $18,680.00 | - | -41.5% | -55.1% | |
| Feb 3, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $20.84 | $5,210.00 | - | -42.9% | -57.2% | |
| Jan 27, 2023 | Patel Snehal61 | CEO And CFO | Buy | 2,000 | $19.35 | $38,700.00 | - | -46.5% | -54.9% | |
| Jan 27, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $19.20 | $4,800.00 | - | -46.5% | -54.9% | |
| Jan 20, 2023 | Patel Snehal61 | CEO And CFO | Buy | 1,500 | $17.37 | $26,055.00 | - | -37.9% | -47.7% | |
| Jan 13, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $16.50 | $4,125.00 | - | -26.4% | -43.1% | |
| Jan 6, 2023 | Patel Snehal61 | CEO And CFO | Buy | 1,500 | $15.18 | $22,770.00 | - | -11.2% | -34.4% | |
| Dec 29, 2022 | Patel Snehal61 | CEO And CFO | Buy | 4,000 | $15.19 | $60,760.00 | +0.1% | -7.6% | -31.1% | |
| Dec 16, 2022 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $13.01 | $13,010.00 | - | +2.2% | -15.3% |